Trial Profile
Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Pharmacokinetics
- 13 Dec 2022 Results (n=40) presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 29 Mar 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
- 29 Mar 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2022.